The app is developed by the Dutch Teratology Information Service (TIS), part of Pharmacovigilance Centre Lareb. The Dutch TIS is the national knowledge center for medication safety during pregnancy and breastfeeding [39]. TIS provides evidence-based information on over 1100 (primarily prescription) drugs through a knowledge bank on its public website, which receives approximately 1.5 million visits annually [40]. Next to the knowledge bank, there was a desire for easier and faster access to information on OTC medications, for example, when standing in the drugstore. Inspired by a widely used Dutch app on the safety of food during pregnancy (the ZwangerHap app; The Netherlands Nutrition Centre) [41], a grant proposal for the development of a new app on the safety of OTC medication was submitted to and approved by the Netherlands Organization for Health Research and Development (ZonMw; grant number: 10140162210007). The 2-year development and implementation project started on May 1, 2023. This study followed a development and formative evaluation approach in which data were collected through questionnaires and focus groups to iteratively refine the new mobile app. This study followed 5 consecutive phases, including preparation, development, preimplementation, implementation, and evaluation (Figure 1). The month numbers displayed in Figure 1 represent the month of the year.

First, a project group consisting of representatives from the professional associations of midwives and gynecologists, as well as a delegate from the umbrella organizations representing drugstores, was assembled. Next, a needs assessment was conducted among the target population using 2 tailored online questionnaires, one for women who were pregnant or gave birth within the past year and one for health care professionals working with this group. These were the only inclusion criteria for participating in the needs assessment. Questions focused on information-seeking behavior, content preferences, and distribution strategies. Given their brief and exploratory nature, the questionnaires primarily assessed opinions and prior behaviors and were therefore not pilot-tested nor formally validated. A translated version of one of the distributed questionnaires is provided as supplemental material. Participants were recruited using convenience and snowball sampling approaches, primarily through the Dutch Pregnancy Drug Registry (as part of the Dutch TIS), social media, an umbrella organization of drugstores, and the TIS’s professional network. Together, these recruitment strategies aimed to provide a comprehensive representation of the target population, thereby reducing the risk of sampling bias. The target sample size of 100 completed questionnaires was determined based on feasibility considerations and the exploratory aims of the study. The completed questionnaires were analyzed descriptively and extensively discussed within the project group, and the outcomes were used as a basis for the development phase.

During the development phase, an initial draft of the app was devised together with a marketing agency and information technology partner. When developing the app prototype, insights from the needs assessment were used, and discussions with the project group addressed which barriers health care professionals needed to overcome before recommending the app. Key decisions included the navigation structure, type of information, required warnings, interface design, app name, and integration with the existing TIS knowledge bank on the website for extended content. A comprehensive list of OTC medicines, such as analgesics, antacids, vitamins, and herbal supplements, was based on the most commonly used OTC medicines during pregnancy in the Dutch Pregnancy Drug Registry and further extended with OTC medicines identified during field visits to pharmacies, drugstores, and supermarkets. Medicine safety information included in the app was drafted by teratology experts from the Dutch TIS, based on the latest scientific available evidence. Content drafting was supervised by a medical doctor and a pharmacist. All displayed content was fully managed in-house, allowing for continuous updates and modifications as needed. Finally, in consultation with legal experts, privacy terms and disclaimers were carefully drafted. By the end of this phase, a fully functional app prototype was completed.

Before the launch, a prototype of the app was extensively tested among the target population using a mixed method approach by collecting both qualitative data (focus groups) and quantitative data (questionnaires). First, focus groups were conducted consisting of target users and teratology experts. Participants were recruited through convenience and snowball-based approaches, primarily via midwifery practices, pregnancy fitness classes, and professional networks. Each focus group was scheduled for a maximum of one hour. Participants first completed exercises designed to facilitate navigation through the app, after which the facilitator led a group discussion following a predesigned script, eliciting feedback aimed at improving the app. Sessions were audio-recorded with consent, and all feedback points were documented and descriptively analyzed without the use of an analytical framework. We aimed to conduct 5 focus groups with a minimum of 5 participants each, a target determined pragmatically in light of feasibility and the short data collection timeframe. Subsequently, an online questionnaire, mirroring the focus group tasks, was distributed among health care providers and women who were pregnant or gave birth within the past year. These were the only inclusion criteria for administering the questionnaire. The aim was to collect 10 completed questionnaire responses. All feedback from the focus groups and questionnaires was evaluated, and final adjustments to the app were made accordingly.

The launch of the app was supported by both broad and targeted communication campaigns. Dissemination relied on an informing strategy, engaging stakeholders to promote the app through online and offline channels. Health care professionals were positioned as key figures by recommending the app during consultations, as part of a motivational approach. Booster campaigns were periodically initiated to reach the continuously changing target population. All feedback received from app users was carefully reviewed, and whenever possible, immediate additions or changes were made to the content.

Evaluation metrics included the number of app downloads, App Store ratings, user feedback, number of daily active users, most searched medications, and total number of page views. Tracking of anonymous in-app user behavior commenced 5 months postlaunch, following an app release. A cautious initial target of 15,000 downloads was set for the first year, based on the approximate annual birth rate of 170,000 in the Netherlands, with the understanding that awareness and adoption would take time to build [42].

This study did not require approval from a medical ethics review committee, as it did not qualify as medical research involving human subjects under the Dutch Medical Research Involving Human Subjects Act. All collected data were anonymized before analysis to protect participant privacy and confidentiality. Participation was voluntary, and informed consent was obtained from all participants prior to participation. Only focus group participants received a gift voucher of their choice as a token of appreciation for their time and contribution.

A total of 217 individuals completed the needs assessment questionnaire; 184 (84.8%) were women who were pregnant or had given birth within the past year, and 33 (15.2%) were health care professionals (Table 1). Among the women, 160 out of 184 (87.0%) were pregnant at the moment of administering the questionnaire (mainly in the second trimester), and 10 out of the 24 women who recently gave birth (41.7%) were still breastfeeding. The majority of women (134/184, 72.8%) reported actively seeking safety information before using any medication. The need for information on OTC medicines (142/184, 77.2%) and health products (eg, supplements, herbs, and vitamins; 122/184, 66.3%) was higher than the need for information on prescribed medicines (70/184, 38.0%). Preferred sources of information were official (government) websites (151/184, 82.1%), product information (125/184, 67.9%), and health care providers (115/184, 62.5%). The primary motivation for seeking safety information was (1) to determine whether a medicine can be used during pregnancy and breastfeeding or not (2), which medicine is the preferred treatment option for specific (pregnancy) complaints, and (3) what the possible adverse drug reactions are. Open-ended responses underscored challenges in finding trustworthy and accessible information, and frustration with inconsistent recommendations across sources.

Health care professionals (n=33) reported using the knowledge bank of TIS on the website frequently and appreciated the clear distinction between pregnancy and breastfeeding guidance. The main reasons for seeking safety information were (1) to determine whether or not a medicine can be used during pregnancy and breastfeeding (2), what the possible adverse drug reactions are, and (3) which medicine is the preferred treatment option for specific (pregnancy) complaints. While some believed the app could reduce their workload, others expected women would still seek personal advice. Finally, health care professionals were moderately likely to use the app themselves (mean 6.0, SD 3.5) but more likely to recommend it to patients (mean 7.3, SD 2.4 out of a scale from 1 to 10).

The primary focus in the user experience testing was to make sure that the required information was found as quickly as possible and was comprehensive and easy to understand. For this purpose, all medicines in the app are classified within 3 risk categories using the traffic light colors, including green (can be used), yellow (be careful and read more information), and red (not to be used). Safety information in the app is distributed through 2 kinds of information pages (Figure 2):

Users can search by active ingredient, brand name, or health complaints. The app name, MediMama (Netherlands Pharmacovigilance Centre Lareb), was selected in collaboration with followers of a large Dutch pregnancy platform. The look and feel of the MediMama app are displayed in Figure 2. Based on user preferences, the app was developed as a native app as well as a web-based version.

The prototype was tested in 5 focus groups (n=23 participants) and via an online questionnaire (n=14; Table 2). During the focus groups, thematic saturation was observed. Participants in the focus groups reported that the app was easy to use, had an appealing look and feel, and the displayed safety information with the 3 colors was a big plus. Minor technical issues were noted on certain devices. Key suggestions included shortening texts, improving ease of reading, removing account registration, improving the disclaimer text, and considering adding more information about medication usage, such as duration and dosage. The online questionnaire was completed by 6 out of 14 (42.9%) women who were pregnant during the administration of the questionnaire or gave birth within one year of completing the questionnaire and 8 out of 14 (57.1%) health care providers with different backgrounds (Table 2). All questionnaire respondents rated the app’s ease of use ≥8/10. Most women reported that they would probably (3/14, 21.4%) or definitely (11/14, 78.6%) use or recommend the app. Suggestions were made to improve specific texts (eg, the disclaimer) and to add references to other sources of information for more detailed information on, for example, medication usage or the health condition. All health care providers agreed with the statement that the information in the app is appropriate and suitable for women who are pregnant or breastfeeding.

The MediMama app was launched on Mother’s Day (May 12th), 2024, and has been freely available in the app stores since then [43,44]. During the first year, the MediMama app was promoted through various channels, with the 4 main promotional strategies being the following:

User feedback led to several app improvements. In response to frequent requests, the most searched prescription medicines were also added. The prescribed medicines in the app all receive the “yellow risk category” (be careful and read more information) and directly refer to the medicine-specific information on the TIS website for more detailed information and the advice to discuss this medication use with their physician.

In its first year, the app was downloaded 22,415 times, averaging 1868 downloads per month (Figure 3). Peak activity occurred in the launch month (n=3963). After the initial peak of reaching the early adopters, the average daily number of downloads gradually increased from 44 per day up to 75 per day. The social media campaign proved to be one of the most effective strategies to reach the target population. On average, app users viewed 3 pages per session; in total, on average, 24,352 pages were viewed each month (Figure 4). The number of daily app users increased from 207 per day to 370 daily app users over the course of 6 months. However, the growth in the number of downloads and app users did not follow a consistent upward trend each month over the course of the first year, resulting in some fluctuation in usage (eg, the short month of February or seasonal changes). To date, the MediMama app has received 11 reviews across both app stores, all of which have awarded it the maximum rating of 5 stars. Most of the feedback received via email and social media concerned the need for the app to be available in multiple languages and to include information on prescribed medications. Paracetamol (acetaminophen) and nasal sprays turned out to be the most frequently searched and viewed medicines in the app (Table 3). While category pages received more overall views, individual pages were more frequently accessed via search. This indicates a distinction in user behavior; searches were primarily aimed at specific medicines, whereas the higher number of views on category pages suggests that users actively navigated through the app to gain a more comprehensive understanding of an entire group of medicines. Finally, seasonal trends in search terms are visible corresponding with the seasonal health complaints (Figure 5). For example, in the flu season (December-February), information-seeking behaviors leaned toward medicines like nasal sprays or cough syrups, while a peak in hay fever medicine (eg, cetirizine tablets) was noticeable from March onward.

This study details the development and dissemination process of MediMama, a Dutch mobile app providing evidence-based information on the safety of OTC medicines and products during pregnancy and breastfeeding. Preimplementation research suggested that the preferred route for receiving safety information on medicine was online and emphasized the need for a new mobile app. Involving the target population throughout development ensured alignment with user needs. One year postlaunch, the MediMama app is considered a promising eHealth tool, addressing the demand for accessible, reliable OTC medicine safety information in maternity care.

Previous eHealth apps in maternity care have demonstrated a successful tool in improving safe medication use and overall maternal health outcomes during pregnancy and lactation [15]. Educational apps and clinical decision support tools have been shown to improve medication adherence, increase antenatal care attendance, and support behavioral changes for topics such as healthy diet, smoking cessation, and vaccination uptake [16,45-47]. Usability and acceptability of mobile health apps during pregnancy are generally high, with pregnant women and health care providers reporting satisfaction and willingness to recommend these tools [16,45,48,49]. Some previously developed apps on the safety of medication use during pregnancy or breastfeeding have been developed, for instance, LactSafe (NIH LactMed - MotherToBaby (OTIS)) [34], MommyMeds (InfantRisk Center) [35], and Meds4Mums2B (Innovative Health Initiative (IHI) ConcePTION, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA)) [36]. The MediMama app differs from existing tools by being freely accessible worldwide, providing comprehensive safety information for both pregnancy and breastfeeding based on scientific literature. In addition, the MediMama app has been scientifically evaluated, and data on usability and user satisfaction are available. Because of limited available evidence, the effectiveness of mobile health apps in improving maternal knowledge, behavior, and perinatal outcomes remains inconclusive [45,50].

Despite their potential, eHealth tools during pregnancy also carry certain risks with regard to self-treatment [19]. Self-medication during pregnancy is prevalent and can lead to inappropriate drug selection, misdiagnosis, dosing errors, delayed medical help–seeking, and inefficient treatment which may result in adverse maternal and fetal outcomes [51,52]. The MediMama app aims to mitigate these risks by using intuitive, color-coded guidance that is immediately interpretable at a glance and by advising on how to treat a complaint through lifestyle changes instead of medicines (ie, for heartburn). With regard to the quality of eHealth apps, previous reviews elaborated on the growing concern over the quality of several (commercial) pregnancy apps with regard to poor or unclear evidence base of content, lack of expert involvement, and poor validation [19,53-56]. Emerging artificial intelligence–based health tools further complicate this landscape, with risks of misinformation due to limited contextualization and transparency [57,58]. To navigate these waters of conflicting health information, health care providers can play a central role in advocating for evidence-based trustworthy health information provided by noncommercial public institutions.

Pregnancy and breastfeeding represent periods of heightened health awareness, yet implementation of interventions is challenging due to the dynamic and transient target population [59,60]. The relatively short duration of pregnancy and the subsequent breastfeeding period means that the target group is constantly changing, with individuals entering and exiting the eligible target population in a matter of months. During the implementation phase of the MediMama app, we also experienced the considerable effort it required to reach this constantly changing target population. We have experienced that focusing on online marketing and involving health care providers in disseminating the app could be a promising and sustainable approach to reaching this constantly changing target population.

This is the first study to systematically describe the development and dissemination process of a mobile app focused on medicine safety in pregnancy and breastfeeding, using mixed methods to capture user and provider perspectives. The diverse set of offline and online strategies used to distribute the MediMama app enabled us to reach this constantly changing target population. Due to this multifaceted promotional approach, the target aim of 15,000 downloads within the first year was reached within the first 7 months. The MediMama app has been well received; the number of daily users keeps increasing, and reviewers praise its simplicity, trustworthiness of the information, and their privacy protection since the app is used anonymously.

However, anonymity limits evaluation of user demographics, hindering assessment of whether the app reaches intended subgroups (eg, pregnant women vs health care providers) and its impact on clinical workload. Consequently, it is difficult to assess whether the app conveys the appropriate tone of voice in presenting safety information. Further user research is therefore needed. Another limitation of our study is that the preimplementation recruitment via the pregnancy registry may have introduced selection bias and the use of unvalidated and not pilot-tested questionnaires to assess user needs. This may have affected the quality and reliability of the collected data. However, the questionnaires were developed in close alignment with the study objectives, supporting their face validity despite the lack of formal validation. Finally, most suggested feedback after the launch of MediMama was making the information in the app available in multiple languages. By limiting the language options to Dutch only, we were likely unable to reach some of the most vulnerable populations, including individuals with limited digital literacy or access, who might benefit most from health guidance. However, vulnerable pregnant women may require additional and fundamentally different forms of health education because a “one-size-fits-all” approach is unlikely to reach a heterogeneous pregnant population with varying levels of health literacy [60].

Prior to the large-scale implementation of mobile health apps during pregnancy, more research is needed on their effectiveness. As previous studies suggested, there is still much to learn on the impact of mobile health apps during pregnancy with respect to cost-effectiveness, potential to reduce health care costs and system burden, and their potential positive effect on maternal and neonatal outcomes [19,45]. Since the MediMama app is freely accessible and operates without a profit-generating model, the lack of secured funding poses a significant risk to its ongoing maintenance and sustainability, potentially jeopardizing its continued availability. Further research is needed to identify sustainable approaches to integrate these interventions within maternity care to ensure their continued maintenance, updating, and optimization. In addition, to reach the entire Dutch population of pregnant and breastfeeding women, establishing and maintaining long-term collaboration with health care professionals, such as midwives and gynecologists, is critical. While the target user group changes over time, health care professionals represent a stable and trusted gateway to this population. Further evaluation of effective strategies to continuously reach the different target populations is warranted. Finally, since the multiplicity of mobile apps in pregnancy can be overwhelming and choosing the best one is proven to be difficult for pregnant women, future efforts should explore unified, multilingual platforms that balance usability with comprehensive, evidence-based content [61].

This study describes the development and dissemination process of the MediMama app, designed to provide easily accessible and evidence-based safety information on OTC medicines during pregnancy and breastfeeding. One year postlaunch, MediMama has been a well-received and frequently used eHealth resource in the Netherlands, effectively meeting the information needs of its target population. While initial feedback and usage patterns of MediMama are promising, the behavioral impact of the app remains untested, and its usability has yet to be formally assessed, warranting further evaluation. Further research is required to evaluate the effectiveness of the implementation strategy, as well as the app’s impact on maternal medication use behaviors and health outcomes. Mobile health is emerging as a pivotal tool in maternity care; increased emphasis is required on the continued development of these tools to improve the health of future generations.